The Ten-Year Survival Rate for Breast Cancer Females in Kurdistan/Iraq: Special Facts and Features
DOI:
https://doi.org/10.15218/crewh.2022.03Keywords:
Ten-Year, Survival rate, Breast Cancer, KurdistanAbstract
Background and objective: Worldwide, breast cancer varies widely in survival rate and age at first diagnosis. Owing to the limited follow up database in developing areas, this study aimed to estimate the 10-years survival rate for breast cancer in Kurdistan/Iraq and correlate it with clinicopathological variables.
Methodology: This follow-up study included 160 breast cancer patients diagnosed before 2010. Their data were obtained from Duhok/central lab. Survivors and families of deceased cases were contacted to approve the survivor. Cases were reviewed for variables including estrogen and HER-2 status.
Results: The mean age of patients was 44.9 years. Only 66 of them (41.2%) survived for 10-years. None of the survivors was below 30 or above 70 years. Death rate was significantly high between 30-39 years. The survival rate was highest (75.8%) between 40-49 years. The lymph nodes involvement was seen in 61.87% with statistically higher mortality rate. Estrogen was positive in > ¾ of patients (76.9%) which was statistically high among survivors. However, in deceased group estrogen positivity was also high (41.88%), while HER-2 were only significant between 40-49 years. Conclusion: The relatively low survival rate, the young age at first diagnosis, despite the high estrogen receptors positivity are facts can’t be explained by delay treatment and need thorough search for a possible genetic or other underling rezone.
References
Balasubramanian R, Rolph R, Morgan C, Hamed H. Genetics of breast cancer: management strategies and risk-reducing surgery. Br J Hosp Med (Lond) 2019 Dec 2;80(12):720-5. doi: 10.12968/hmed.2019.80.12.720 2. Siegel RL, Miller KD, Jemal A. Cancer Statistics. CA Cancer JClin 2017 Jan;67(1):7-30. doi:10.3322/caac.21387. 3. McGuire S. World Cancer Report. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015.Adv Nutr 2016 Mar 15;7(2):418-9. doi: 10.3945/an.116.012211.
Stewart BW, and Kleihues P. (Eds): World Cancer Report. IARCPress. Lyon 2003. Archived 20 October 2008 at the Wayback Machine.
Wyld L, Markopoulos C, Leidenius M, Senkus-Konefka E. Breast cancer management for surgeons: a European multidisciplinary textbook. 2018; 580; 978-3-319-56671-9. 6. Solomon T, Racheta B, Whitehead S, Coleman MP. Cancer Survival in England Patients Diagnosed: 2007-2011 and Followed up to 2012: Comparisons across 24 cancer types of the rate of survival for adults (aged 15 to 99) and short-term predicted survival rates for recently diagnosed patient. ONS 29 October 2013. 7. "World Cancer Report". International Agency for Research on Cancer. 2008. Archived from the original (PDF) on 20 July 2011. Retrieved 26 February 2011. 8. "Breast Cancer: Breast Disorders: Merck Manual Professional". Merck.com. Archivedfrom the original on 10 November 2011. Retrieved 8 May 2010.
Zheng YZ, Wang L, Hu X, Shao ZM. Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study. Oncotarget 2015 Sep 8;6(26):22985-95. doi: 10.18632/oncotarget.3945 10. Liu P, Li X, Mittendorf EA, Li J, Du XL, He J, et al. Comparison of clinicopathologic features and survival in young American women aged 18-39 years in different ethnic groups with breast cancer. Br J Cancer 2013 Sep 3;109(5):1302-9. doi: 10.1038/bjc.2013.387. 11. Peppercorn J. Breast cancer in women under 40. Oncology (Williston Park) 2009 May;23(6):465-74. 12. Mates M, Fletcher GG, Freedman OC, Eisen A, Gandhi S, Trudeau ME, et al.Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol 2015 Mar; 22(Suppl 1): S114–S122. doi: 10.3747/co.22.2322. 13. Le XF, Pruefer F, Bast RC Jr. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways.Cell Cycle 2005 Jan;4(1):87-95. doi: 10.4161/cc.4.1.1360. 14. Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus NM, Piccart MJ,et al. Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) ER positive breast cancer. BMC Med Genomics 2009 Jun 24;2:37. doi:10.1186/1755-8794-2-37. 15. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008 Dec 4;456(7222):663-6. doi: 10.1038/nature07483. 16. Özmen V, Özmen T, Doğru V. Breast Cancer in Turkey; An Analysis of 20.000 Patients with Breast Cancer. Eur J Breast Health 2019 Jul 1;15(3):141-6. doi: 10.5152/ejbh.2019.4890. 17. Yedjou CG, Sims JN, Miele L, Noubissi F, Lowe L, Fonseca DD, et al. Health and Racial Disparity in Breast Cancer. Adv Exp Med Biol 2019;1152:31-49. doi: 10.1007/978-3-030-20301-6_3 18. Yalda MI. Estrogen and Progesterone Receptors (ER and PR) Status of Breast Cancer Cases in Kurdistan and Their Correlation with Pathologic Prognostic Variables. Med. j. Babylon 2013; 10 (1): 75-84. 19. Majid RA, Mohammed HA, Saeed HM, Safar BM, Rashid RM, Hughson MD. Breast cancer in Kurdish women of northern Iraq: incidence, clinical stage, and case control analysis of parity and family risk. BMC Womens Health 2009 Dec 11;9:33. doi: 10.1186/1472-6874-9-33 20. Elkum N, Dermime S, Ajarim D, Al-Zahrani A, Alsayed A, Tulbah A, et al. Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience. BMC Cancer 2007 Dec 5;7:222. doi: 10.1186/1471-2407-7-222. 21. Omar S, Khaled H, Gaafar R, Zekry AR, Eissa S, et al. Breast cancer in Egypt: a review of disease presentation and detection strategies. EMHJ 2003 May ;9(3):448-63. https://apps.who.int/iris/handle/10665/119297 22. Al-Janabi A.A. Immunohistochemical study of p53-onco-suppressor gene in correlation to other biochemical markers in breast cancer (a prospective study). 2003. Thesis. 23. Özmen V. Breast Cancer in Turkey: Clinical and Histopathological Characteristics (Analysis of 13.240 Patients). J Breast Health 2014 Apr 1;10(2):98-105. doi: 10.5152/tjbh.2014 24. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2016. National Cancer Institute. Bethesda, MD. Accessed on May 7, 2019. http://seer.cancer.gov/csr/1975_2016/, 2019 25. Radecka B, Litwiniuk M. Breast cancer in young women. Archived 10 September 2009 at the Wayback Machine WebMD. Ginekol Pol 2016; 87(9):659-63. doi: 10.5603/GP.2016.0062.
Welch HG, Prorok PC, O'Malley AJ, Kramer BS. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. N Engl J Med 2016 Oct 13;375(15):1438-47. doi: 10.1056/NEJMoa1600249 27. Peppercorn J."Breast Cancer in Women Under 40". Oncology 2009; 23(6):46574. PMID 19544685. Archived from the original on 16 June 2009.] 28. Shavers VL, Harlan LC, Stevens JL. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 2003 Jan 1;97(1):134-47. doi: 10.1002/cncr.11051 29. Biffl WL, Myers A, Franciose RJ, Gonzalez RJ, Darnell D. Is breast cancer in young Latinas a different disease? Am J Surg 2001 Dec;182(6):596-600. doi: 10.1016/s0002-9610(01)00789-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Mayada Yalda
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
